Search results
Bionomics secures $70 million in private placement By Investing.com
Investing.com· 4 days agoBionomics Limited (NASDAQ: BNOX), a clinical-stage biotech company, announced a private placement...
Snowflake unveils new AI development tools at summit By Investing.com
Investing.com· 5 hours agoThe new offerings include Snowflake Notebooks, Snowflake Trail, and a series of DevOps tools, which...
‘Hot Dog Money’ Review: The Broker Who Broke Bad
The Wall Street Journal· 1 day agoBy 2006 the broker had relationships with more than a dozen NFL players as well as prospects in the pipeline. His services extended beyond stock tips,...
Q1 2025 Science Applications International Corp Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 14 hours agoIn other words, we expect an improvement in the overall quality of our pipeline and submissions as we increase volume. Before turning the call over to Prabu to discuss our ...
Cytokinetics shares price target cut on strategic funding collaboration By Investing.com
Investing.com· 5 hours agoB.Riley has adjusted the stock price target for Cytokinetics (NASDAQ:CYTK), bringing it down to...
RBC maintains FactSet's stock rating, cites Q4 ASV growth and market challenges By Investing.com
Investing.com· 6 days agoThe firm anticipates FactSet to report third-quarter 2024 results that align with expectations,...
BofA Securities sets price target on ZEEKR shares with buy rating By Investing.com
Investing.com· 12 hours agoThe new price objective suggests a 37% potential upside from the company's current trading level....
Fargo trims Immunovant stock price target following pipeline update By Investing.com
Investing.com· 4 days agoOn Friday, Wells Fargo adjusted its price target on shares of Immunovant (NASDAQ:IMVT), lowering it...
Deutsche Bank cuts Phillips Edison shares target, cites interest rate concerns By Investing.com
Investing.com· 6 days agoAdditional concerns included the potential impact of rising interest rates on the company's bottom...
Coherus Biosciences retains Buy rating on strong launch progress By Investing.com
Investing.com· 5 days agoOn Thursday, Coherus Biosciences (NASDAQ:CHRS) maintained its Buy rating from TD (TSX:TD) Cowen,...